Why a Concentration Needs Its Context
A laboratory concentration is a measurement, not a complete description of a dosing event. The same reported value can have different meanings depending on what was administered, when it was administered, when the sample was collected, and what the assay measured. A concentration cannot be reliably placed in a dosing interval—or compared with another result—until those details are known.
Earlier material on recording sample time relative to dosing and on sampling at steady state established why dose-to-sample timing and the patient’s dosing history matter. Here the focus is the minimum metadata needed to make those facts usable and auditable. The goal is not to force an interpretation when records are incomplete. It is to identify what is known, what remains uncertain, and which conclusions therefore cannot be supported.
The Minimum Record
A practical record should distinguish what was prescribed from what was taken or administered. A prescription is evidence of the intended regimen, not proof that each dose was received at the scheduled time. For interpretation, document the actual dose history when available, including the dates and times of recent doses and any missed, delayed, extra, or changed doses. If the exact history is unavailable, record that uncertainty rather than silently substituting the prescription schedule.
The record also needs enough detail to identify what “a dose” means. Include the drug, strength, amount administered, formulation, and route. For an infusion, record the infusion start and stop times and the delivered amount or rate. For an oral product, distinguish formulations when relevant, such as immediate-release and extended-release products. A change in formulation or route can change the concentration-time profile even when the listed drug and nominal dose are the same.
Record the actual sample collection date and time, not only the time the sample arrived in the laboratory or was entered into a system. Use a consistent time zone and note any uncertainty in the timestamp. The elapsed time since a relevant dose can then be calculated as sample time minus dose time. For a trough, peak, or other intended sampling point, record that intended label separately: the label does not replace the actual times.
| Metadata group | Minimum details to capture | Why it matters |
|---|---|---|
| Drug and regimen | Drug, prescribed regimen, actual administered amount, and recent dose dates and times | Establishes what exposure history the result follows |
| Product and administration | Formulation, strength, route, and, for an infusion, start and stop times | Identifies how the dose entered the body and the relevant dosing event |
| Sample | Collection date and time, including time zone when relevant | Allows dose-to-sample timing to be determined |
| Measurement | Analyte, specimen matrix, assay or laboratory, result, units, and any reported qualifier | Identifies what was measured and how the value is expressed |
The measurement details are not administrative decoration. A result for parent drug is not interchangeable with a result for a metabolite. Plasma, serum, and whole-blood results are not automatically equivalent. Units must be explicit, and a result below a quantification limit or flagged by the laboratory should retain that qualifier. The earlier material on analytical uncertainty addresses uncertainty in the measurement; here, the essential task is to preserve enough assay information to know which measurement the reported number represents.
Other clinical information may be needed for a specific pharmacokinetic model or clinical decision. It does not replace the minimum record above. In particular, a complete set of timestamps cannot compensate for not knowing the formulation, and an exact dose history cannot identify the meaning of a result whose analyte or units are unclear.
Worked Example: A Two-Hour Timing Error
Consider a hypothetical patient after a single intravenous bolus dose. Assume that the measured concentration is in the post-distribution elimination phase and that elimination follows \(C(t)=C_0e^{-kt}\), with \(k=0.100\ \mathrm{h}^{-1}\). The laboratory reports \(4.00\ \mathrm{mg/L}\). What would a two-hour uncertainty in the dose-to-sample time do to a back-extrapolated concentration?
If the dose was given at 08:00 and the sample collected at 16:00, the elapsed time is \(t=8\) h. Under the stated model, the back-extrapolated value is
If the dose was actually at 06:00, the elapsed time is \(t=10\) h, and the same calculation gives \(4.00\times e^{1.000}=10.9\ \mathrm{mg/L}\). Thus, the reported concentration alone does not determine the back-extrapolated value; the dose timestamp is essential. These values are model-based illustrations, not clinical estimates: the calculation assumes the specified elimination model and known \(k\), and it would not apply without qualification if the sample were still in distribution or the stated dose were not the actual dose.
How Missing Details Change Interpretation
The role of timing can be stated directly. During a phase described by \(C(t)=C_0e^{-kt}\), a timing error of \(\delta\) hours changes the concentration predicted at the later time by a factor of \(e^{-k\delta}\). For example, with \(k=0.100\ \mathrm{h}^{-1}\) and a two-hour difference, the factor is \(e^{-0.200}=0.819\). The later-time prediction is about 18.1% lower than the earlier-time prediction. This derivation assumes the same exponential elimination phase and a positive \(\delta\); it does not establish that a real patient follows that model.
This illustrates a general point: metadata are inputs to an interpretation, not optional annotations added after the calculation. The interpretation may be sensitive to one field and relatively insensitive to another, but that cannot be judged until the field is known and the relevant model or sampling purpose is specified.
Worked Example: Same Nominal Dose, Different Formulation
A hypothetical record says only “100 mg orally at 08:00,” and a sample was collected at 10:00. The product could have been immediate-release or extended-release. The elapsed time is two hours in either case:
That arithmetic does not establish that the sample represents the same part of the concentration-time profile for both products. The formulation is missing, and the time course after an immediate-release product need not match that after an extended-release product. Therefore, “two hours after a 100 mg oral dose” is an incomplete description for interpreting this sample. The correct conclusion is not that one formulation produced a higher concentration; no concentration values or product-specific model have been supplied. The supported conclusion is that the formulation must be recovered from the medication record, package, or another reliable source before assigning a formulation-specific meaning to the sample.
This example also shows why “same nominal dose” is not enough metadata. Drug, amount, route, formulation, administration time, and sample time must be recorded together.
Assay Identity and Comparable Results
Before comparing two reported concentrations, verify that they refer to the same analyte, specimen type, and compatible units. A result for a parent drug should not be treated as a result for the parent plus metabolite unless the assay and report explicitly define it that way. Similarly, a numeric comparison is meaningless if one result is in \(\mathrm{mg/L}\) and the other is in \(\mathrm{ng/mL}\) and no conversion has been made.
Worked Example: Checking Units Before Comparing Results
A hypothetical report gives a concentration of \(2.40\ \mathrm{mg/L}\). A second report for the same analyte and specimen type gives \(1{,}800\ \mathrm{ng/mL}\). Convert the first result and compare the reported values.
Since \(1\ \mathrm{mg}=1{,}000{,}000\ \mathrm{ng}\) and \(1\ \mathrm{L}=1{,}000\ \mathrm{mL}\), it follows that \(1\ \mathrm{mg/L}=1{,}000\ \mathrm{ng/mL}\). Therefore,
On this common scale, \(2{,}400\ \mathrm{ng/mL}\) is \(600\ \mathrm{ng/mL}\) greater than \(1{,}800\ \mathrm{ng/mL}\), or \(2{,}400/1{,}800=1.33\) times as large. This is a comparison of the stated numbers after unit conversion, not proof of a biological change. It is only appropriate if the analyte and specimen are also comparable and the reports identify what was measured. If one result is whole blood and the other plasma, or one measures a different analyte, this arithmetic alone does not make them interchangeable.
A Practical Metadata Check
A concise check can prevent an unsupported conclusion before any concentration-based calculation is attempted. Work through the fields in order, preserve source information, and mark unknown values explicitly.
Record the drug, analyte, result, units, specimen matrix, laboratory or assay information, and any qualifier such as a below-quantification report.
Verify dose amount, strength, formulation, route, and administration time. For an infusion, record start and stop times. Distinguish documented administration from a prescribed schedule or an uncertain recollection.
Record recent doses and any missed, delayed, extra, or changed doses that bear on the intended interpretation. Do not assume a regular schedule when the record indicates otherwise or is incomplete.
Use the collection date and time to calculate the interval from the relevant dose. Keep the intended sampling label separate from the observed timestamps.
If a required field is unknown, state which interpretation depends on it. Do not replace missing information with an unlabelled assumption.
This checklist is not a dosing algorithm. A correctly documented sample can still require a pharmacokinetic model, clinical context, or additional measurements to answer a particular question. Conversely, an apparently plausible result should not be used to fill in an undocumented dose time or identify an unknown formulation.
Common Pitfalls and Alternatives
- Treating the prescription as the dose history. The wrong reasoning is that a scheduled dose time proves the dose was taken then. The correction is to record actual administration when known and distinguish it from the intended schedule.
- Recording only “trough” or “peak.” These labels do not supply an actual collection time or establish that the sample was collected at the intended point. Keep the label, dose time, and sample time as separate fields.
- Leaving out formulation or route. A drug name and amount do not fully describe an administration. Record product formulation and route, and infusion times when applicable.
- Comparing numbers before checking units and analyte. Convert compatible units only after confirming that the results refer to the same analyte and comparable specimen types.
- Filling gaps with plausible assumptions. A guessed timestamp may yield a precise calculation, but precision does not make the input factual. Label assumptions and avoid conclusions that depend on unverified details.
A standardized, protocol-timed sample can reduce uncertainty about the intended sampling point, whereas an opportunistic sample may be useful when its actual timing and dose history are well documented. Neither approach removes the need to identify the formulation, route, and measurement. Concentration-to-dose ratios, paired peak-and-trough sampling, and AUC-based approaches answer different monitoring questions, but each still depends on correctly identified doses, samples, and assay results. No calculation method can reconstruct a missing fact from the concentration alone.
The limits are important: metadata can establish what happened and what was measured, but do not by themselves establish the patient’s pharmacokinetic parameters, explain a clinical response, or determine an appropriate dose. If essential information cannot be recovered, the defensible outcome may be to qualify or withhold a particular interpretation rather than to select the most convenient assumption.
Check Your Understanding
For each question, identify the metadata issue and give the supported conclusion.
- A sample is called a “trough,” but the dose and collection timestamps are absent. What can and cannot be concluded?
- A patient’s record lists 50 mg every 12 hours, while the patient reports that the last dose was taken 15 hours before collection. What should be recorded, and which elapsed time should be used?
- Convert \(0.75\ \mathrm{mg/L}\) to \(\mathrm{ng/mL}\).
- Two values are both reported as \(3.0\ \mathrm{mg/L}\), but one is a parent-drug plasma result and the other is a whole-blood result for parent drug plus metabolite. Can they be treated as equivalent? Why?
Solutions. (1) “Trough” is the intended or reported sampling label, but without actual dose and collection times the dose-to-sample interval cannot be verified. One cannot establish that the sample was collected at a particular interval after a dose. (2) Record both the prescribed schedule and the reported actual dose history, marking the source of the latter. If the patient’s report is the best available account of actual administration, the interval from that reported dose to collection is 15 h; do not substitute the scheduled 12-hour interval. (3) \(0.75\ \mathrm{mg/L}\times1{,}000=750\ \mathrm{ng/mL}\). (4) No. The analyte definition and specimen matrix differ, so equal numeric values and units do not make the measurements equivalent.